IDH2 and cancer: Thus, these results implicate that the activity of wild type IDH, not the cancer-related one, is linked to DJ-1-associated PD, suggesting that the drugs developed to target cancer-related IDH mutant enzymes are not appropriate to treat DJ-1-associated PD.